PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16897985-11 2006 The varying efficiency is thought to be due to the presence of certain polymorphisms in the CYP2A6 gene responsible for metabolizing tegafur to 5-fluorouracil. Tegafur 133-140 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 92-98 18212800-2 2008 Tegafur has been shown to be converted enzymatically to 5-FU to exert its antitumor effect, and this conversion is principally catalyzed by CYP2A6. Tegafur 0-7 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 140-146 12042667-3 2002 Since cytochrome P450 2A6 (CYP2A6) has been reported to metabolize FT to yield 5-fluorouracil (5-FU), it was postulated that the poor metabolic phenotype of patient 1 was caused by mutations of the CYP2A6 gene. Tegafur 67-69 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 6-25 16145066-1 2005 PURPOSE: The conversion rate of tegafur (a component of S-1) to fluorouracil (FU) differs in Asians and whites because of polymorphic differences in the CYP2A6 gene. Tegafur 32-39 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 153-159 15618749-5 2003 The formation of 5-FU from FT in human liver S9 was inhibited over 82% by 8-methoxypsoralen, a CYP2A6-selective inhibitor. Tegafur 27-29 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 95-101 12172220-1 2002 CYP2A6 is known as an enzyme responsible for the metabolism of several clincally used drugs such as tegafur. Tegafur 100-107 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 0-6 12042667-3 2002 Since cytochrome P450 2A6 (CYP2A6) has been reported to metabolize FT to yield 5-fluorouracil (5-FU), it was postulated that the poor metabolic phenotype of patient 1 was caused by mutations of the CYP2A6 gene. Tegafur 67-69 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 27-33 11106261-0 2000 Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Tegafur 17-24 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 59-79 11376561-2 2001 CYP2A6-expressing cells (DLD-1 / CYP2A6 cells) more efficiently catalyzed the conversion of FT to 5-fluorouracil (5-FU) (2.6-fold) and the 7-hydroxylation of coumarin (7.9-fold) than cells transfected with a null construct (DLD-1 / null cells). Tegafur 92-94 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 0-6 11376561-2 2001 CYP2A6-expressing cells (DLD-1 / CYP2A6 cells) more efficiently catalyzed the conversion of FT to 5-fluorouracil (5-FU) (2.6-fold) and the 7-hydroxylation of coumarin (7.9-fold) than cells transfected with a null construct (DLD-1 / null cells). Tegafur 92-94 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 33-39 29996281-2 2018 Tegafur is the major active prodrug, which is metabolized to 5-Fu by cytochrome P4502A6 (CYP2A6). Tegafur 0-7 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 89-95 25002745-0 2014 Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity. Tegafur 69-76 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 10-16 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 233-249 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 251-257 26715117-1 2017 BACKGROUND: Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). Tegafur 47-54 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 98-117 26715117-1 2017 BACKGROUND: Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). Tegafur 47-54 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 119-125 21521021-0 2011 Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Tegafur 91-98 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 24-30 22322240-2 2012 Cytochrome P450 2A6 (CYP2A6) is the principal enzyme responsible for bioconversion of tegafur to 5-FU. Tegafur 98-105 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 0-19 22322240-2 2012 Cytochrome P450 2A6 (CYP2A6) is the principal enzyme responsible for bioconversion of tegafur to 5-FU. Tegafur 98-105 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 21-27 23982118-8 2013 The exploratory pharmacokinetic/pharmacogenetic study showed that CYP2A6 variants (*4, *7, *9) are associated with a lower metabolic ratio of S-1 (exposure ratio of 5-fluorouracil to tegafur). Tegafur 183-190 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 66-72 21521021-1 2011 AIM: Tegafur is primarily converted to 5-fluorouracil (5-FU) by CYP2A6 in the human liver to exert its antitumor effect. Tegafur 5-12 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 64-70 20463005-5 2010 Succinaldehyde (SA) and 4-hydroxybutanal (4-OH-BTL) were produced as the metabolites because of the cleavage of the furan ring of FT during its conversion to 5-FU in cDNA-expressed CYP2A6 and purified TPase, respectively; however, GBL/GHB was hardly detected in cDNA-expressed CYP2A6 and purified TPase. Tegafur 130-132 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 181-187 20463005-5 2010 Succinaldehyde (SA) and 4-hydroxybutanal (4-OH-BTL) were produced as the metabolites because of the cleavage of the furan ring of FT during its conversion to 5-FU in cDNA-expressed CYP2A6 and purified TPase, respectively; however, GBL/GHB was hardly detected in cDNA-expressed CYP2A6 and purified TPase. Tegafur 130-132 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 277-283 19604090-1 2009 AIMS: S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. Tegafur 46-53 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 102-108